PharmTech Drug Digest 11.20
News|Articles|May 28, 2015

Innovative Inhaled Antipsychotic Formulation Adasuve Provides Quick and Effective Treatment

Experts attending the European Psychiatry Association Congress in Vienna say that Adasuve has made an impact in the treatment of agitation in patients suffering from schizophrenia or biopolar I disorder.

Adasuve, an oral inhalation product that combines the patented Staccato system with the antipsychotic loxapine, was approved by EMA in February 2013. The formulation has since benefitted 5000 patients in Europe, according to Rudolf Widmann, CEO of AOP Orphan, speaking at the European Psychiatry Association Congress in Vienna. Experts at the event also confirmed that Adasuve has made an impact in the treatment of agitation in patients suffering from schizophrenia or biopolar I disorder. 

In the Staccato system, loxapine is evaporated to produce an aerosol that is absorbed by the lungs. The drug is transported into the systemic circulation through the lungs, and patients notice a decrease in agitation within 10 minutes.

Available in doses of 9.1 mg, Adasuve is indicated to control cases of mild or moderate agitation in patients suffering from schizophrenia or bipolar I disorder. Patients prefer this non-invasive treatment option to an injection.

 


Related to this article

white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.
Transitioning mRNA from R&D to GMP
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, discusses the R&D-to-GMP transition and the changing shape of mRNA manufacturing facilities.